- Home
- DNP vs SLNO Comparison
DNP vs SLNO Comparison
Compare DNP & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNP
- SLNO
- Stock Information
- Founded
- DNP 1986
- SLNO 1999
- Country
- DNP United States
- SLNO United States
- Employees
- DNP N/A
- SLNO N/A
- Industry
- DNP Investment Managers
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- DNP Finance
- SLNO Health Care
- Exchange
- DNP Nasdaq
- SLNO Nasdaq
- Market Cap
- DNP 3.8B
- SLNO 3.7B
- IPO Year
- DNP N/A
- SLNO 2014
- Fundamental
- Price
- DNP $10.11
- SLNO $48.65
- Analyst Decision
- DNP
- SLNO Strong Buy
- Analyst Count
- DNP 0
- SLNO 10
- Target Price
- DNP N/A
- SLNO $110.90
- AVG Volume (30 Days)
- DNP 479.6K
- SLNO 2.3M
- Earning Date
- DNP 01-01-0001
- SLNO 11-04-2025
- Dividend Yield
- DNP 7.88%
- SLNO N/A
- EPS Growth
- DNP N/A
- SLNO N/A
- EPS
- DNP 2.30
- SLNO N/A
- Revenue
- DNP $154,887,179.00
- SLNO $98,675,000.00
- Revenue This Year
- DNP N/A
- SLNO N/A
- Revenue Next Year
- DNP N/A
- SLNO $181.30
- P/E Ratio
- DNP $4.26
- SLNO N/A
- Revenue Growth
- DNP 3.30
- SLNO N/A
- 52 Week Low
- DNP $8.69
- SLNO $41.50
- 52 Week High
- DNP $10.04
- SLNO $90.32
- Technical
- Relative Strength Index (RSI)
- DNP 52.09
- SLNO 38.14
- Support Level
- DNP $9.96
- SLNO $46.82
- Resistance Level
- DNP $10.22
- SLNO $50.04
- Average True Range (ATR)
- DNP 0.11
- SLNO 3.65
- MACD
- DNP -0.01
- SLNO -0.83
- Stochastic Oscillator
- DNP 62.70
- SLNO 22.23
About DNP DNP Select Income Fund Inc.
DNP Select Income Fund Inc is a closed-ended investment management fund. The primary investment objectives of the fund are current income and long-term growth of income. Its secondary objective is capital appreciation. The Fund seeks to achieve its investment objectives by investing in the public utility industry.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.